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ABSTRACT:
Objective -  To systematically evaluate the efficacy of double dose of 
sulfadoxine-pyremithamine (SP/SP) treatment in pregnancy in malaria 
endemic areas.
Methods - The relevant articles were retrieved by a computerized search of 
Medline, Cochrane Review, Pub Med and Google with the following key 
words, sulfadoxine-pyrimethamine, intermittent, pregnancy, Quasi- 
experimental studies and Randomised Control Trials. Three reviewers 
identified only 2 papers meeting the inclusion criteria set for the study. 
Systematic quantitative review was performed.
Results -  2 papers were included in the meta-analysis. The protective 
efficacy of SP/SP on peripheral parasitaemia was 86% (95% Cl 88%, 91%) 
with risk ratio (RR) of 0.14 (95% Cl 0.09, 0.22). The protective efficacies of 
SP/SP on placental parasitaemia and severe anaemia were 56%(95% Cl 
29%, 73%) and 39% (95% Cl 16%, 55%) respectively. No significanct efficacy 
of SP/SP was shown on low birth weight (LBW) outcome.
Conclusion -  Limited available information show that SP/SP treatment during 
pregnancy has a positive impact on peripheral parasitaemia, placental 
parasitaemia and severe anaemia, such an effect not clearly demonstrated for 
LBW. Therefore, Further evidence is required to fully describe the efficacy of 
SP/SP in pregnancy.
iii
ACKNOWLEDGEMENTS:
I wish to thank all the staff of School of Public Health of the University of the 
Witwatersrand for providing me with the experience necessary to make this 
report possible.
I am indebted to my colleagues who have read early drafts this report with 
care.
Many thanks to my supervisors Dr Danuta K and Dr Spo for their dedicated, 
conscientious, tireless, criticism and constructive guidance which led to my 
successful completion of this report.
Lastly, but not least I would like to thank my sponsor WHO/TDR and Ifakara 
Health Research and Development Director, Dr Hassan Mshinda for his 
encouragement.
IV
DECLARATION:..........................................................................................................II
ABSTRACT:.................................................................................................................Ill
ACKNOWLEDGEMENTS:....................................................................................... IV
1.0 INTRODUCTION:....................................................................................................1
1.1 Malaria burden in general; .............................................................................. 1
1.2 Malaria in pregnancy:........................................................................................1
1.3 The epidemiology of malaria in pregnancy in Africa: ................................1
1.4 The clinical consequences of malaria infections in pregnancy: ............ 2
1.5 The impact of malaria in pregnancy on communities and health............ 4
Services in Africa: .................................................................................................... 4
1.6 Treatment and preventive measure of malaria in pregnancy:.................6
1.7 Questions to be addressed in this study: ....................................................... 7
2.0 METHODS:............................................................................................................... 9
2.1 Search Strategy: ................................................................................................ 9
2.2 Selection criteria: ..............................................................................................9
2.3 Quality assessment:.......................................................................................... 10
2.4 Data extraction:............................................................................................... 10
2.5 Data Analysis: ...................................................................................................12
3.0 RESULTS:............................................................................................................... 13
3.1 Search outcomes: .............................................................................................. 13
3.2 Table of results for data analysis: ............................................................. 16
4.0 DISCUSSION:......................................................................................................... 19
5.0 CONCLUSION AND RECOMMENDATIONS:...............................................23
APPENDICES............................................................................................................... 24
Appendix 1: Study 1:................................................................................................ 24
Appendix 2: Study 2 :................................................................................................ 25
REFERENCE:............................................................................................................... 26
v
1.0 INTRODUCTION:
1.1 Malaria burden in general;
Malaria is the most public health problem facing over 2.4 billion people in over 
90 countries. It is the major cause of death and morbidity. About 200-300 
million clinical cases of malaria occur annually with mortality of one million 
people (1). Approximately 90% of these deaths occur in Sub-Saharan Africa 
(2 ).
In Sub-Saharan Africa malaria is mainly stable with high or moderate 
transmission in many areas. Other areas e.g. East Africa high lands, 
Zimbabwe, South Africa; malaria is unstable with low transmission and 
potential for epidemic (3).
1.2 Malaria in pregnancy:
Each year, approximately 24 million African women become pregnant in 
malaria-endemic areas, and they are at risk of malaria infection during 
pregnancy (4). It is common knowledge that pregnant women are more 
susceptible to infection of many diseases, which may be serious, and life 
threatening (5). Pregnant women are the most risk group to contact malaria. 
When a woman is pregnant her immunity is reduced, making her more 
vulnerable to malaria with dangerous consequences for mother and her child 
(6). That is why the prevalence of malaria higher among pregnant as 
compared to non-pregnant women (7). The effects of malaria to women are 
greatest in their first pregnancy (primigravidae), but they do extend into their 
second or even third pregnancy.
1.3 The epidemiology of malaria in pregnancy in Africa:
The epidemiology of malaria in pregnancy differs greatly with the women’s
pre-existing level of immunity to the malaria. This depends largely on whether
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malaria transmission is high to moderate transmission (Stable Malaria) or low 
transmission (Unstable Malaria) (1). In areas with intense stable transmission 
(e.g. large part of Sub-Saharan Africa); malaria is often asymptomatic 
(occasionally mild fever), severe maternal anaemia is common, peripheral 
parasitaemia often at low level, placental infection is common and often heavy 
and the effects on the foetus lead to cause low birth weight (8).
Areas with unstable malaria (e.g. endemic parts of southeast Asia, South 
America); the effects of malaria in non-immune pregnant women include; 
uncomplicated malaria with high fever, severe malaria with high risk of 
maternal and foetal death, abortion, stillbirth, and LBW (9). This also include 
severe malarial anaemia is a common and very dangerous complication in 
pregnancy (10,11)
1.4 The clinical consequences of malaria infections in pregnancy;
The consequences of malaria infections in pregnant women consist of
maternal and fetal effects. The maternal effects include severe anaemia,
cerebral malaria, Hypoglycaemia, pulmonary oedemal, high fever and
placental infection. The fetal effects include low birth weight, abortion,
congenital malaria and fetal malaria (12).
This review looks at consequences of anaemia, low birth weight, peripheral 
infection and placental infection in pregnant women.
Anaemia in pregnancy is usually multifactorial. The main causes of anaemia 
among women in Sub-Saharan Africa are malaria, iron deficiency, folate
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deficiency, sickle cell disease and advanced HIV disease (12,13,14). Malarial 
anaemia is not primarily iron deficiency anaemia because the mechanism for 
anaemia in malaria causes destruction of red blood cells which releasing 
haemoglobin from the body, which may be excreted through the urine (15).
Generally, maternal deaths due to malaria are caused by severe anaemia in 
high transmission areas although other complications of severe malaria (e.g. 
cerebral malaria, pulmonary oedema) are also occur in this setting and many 
women enter labour with dangerously low haemoglobin (15,16). According to 
WHO report of 1993 over 50% of pregnant women in Sub-Saharan Africa may 
be anaemic (Hb < 11 g/dl) and 5-15% have severe or very severe anaemia 
(Hb < 7g/dl) (17). Pregnant women with severe anaemia at any level of 
malaria transmission are at great risk of mortality from obstetric haemorrhage 
and heart failure (13,15).
Other effects are peripheral and placental malarial parasitaemia. It has been 
reported that women with the first pregnancy usually have a higher 
prevalence of malaria infection (peripheral or placenta) as compared to the 
women that have had pregnancies before (18). Malaria infection of the 
placenta is a major contributor to low birth weight (LBW)(19).
The LBW (<2500g) is the greatest single risk factor for neonatal and early 
infant death (20). In African primigravidae one in four babies has low birth 
weight and malaria may be the cause of low birth weight up to 50% of 
deliveries (21). The relative risk for low birth weight is associated with women 
who experience pregnancy for the first time (22). Low birth weight is also 
associated with significant increased risk of neonatal and infant morbidity.
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Other underlying causes of low birth include maternal anaemia and high fever 
(1). At all levels of transmission, malaria during pregnancy especially in 
primigravidae is associated with low birth weight.
1.5 The impact of malaria in pregnancy on communities and health 
Services in Africa:
Malaria in pregnancy is associated with increase morbidity and mortality, 
which occur among women, mainly in Africa, Table 1. Data from Angola and 
Mozambique have shown maternal mortality rate of 1,500 per 100,000 births 
in both (23). It is estimated that 20% of all maternal deaths are due to severe 
anaemia during pregnancy (13). The pregnant women at risk of malaria are 
also substantial, for example in 1990 it counted 1,191,600 pregnant mothers 
were at risk of malaria in Tanzania (23).
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Table 1: Maternal Mortality and the Malaria burden (23)
Country No. of pregnant women 
at risk
Maternal mortality rate 
per 100,000 births 
(1990)
Angola 568,000 1,500
Botswana 21,600 250
Malawi 493,000 560
Mozambique 682,000 1500
Namibia 38,940 370
South Africa 131,100 230
Swaziland 10,200 560
Tanzania 1,191,600 770
Zambia 368,000 940
Zimbabwe 219,000 570
Generally, morbidity due to malaria overburdens the health system in African 
countries. For instance, in Tanzania malaria morbidity has been reported as a 
leading cause of outpatient consultations accounting from 24.8% to 42.2% of 
the outpatient cases in 1991 (24).
The costs for control and treatment of malaria are also extremely high, it has 
been estimated that malaria cost over US$ 2 billion to the economy in Africa 
alone annually (25).
Malaria also contributes to a considerable burden in endemic communities 
with premature deaths, disability from illness and it impedes on social and 
economic development (26).
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1.6 Treatment and preventive measure of malaria in pregnancy:
It goes without saying that pregnant women need preventive and curative
care in order to prevent or reduce maternal and infant mortality together with
reduction of economic burden of malaria. Control of falciparum malaria in
pregnancy depends on the level of transmission and it is based on a
combination of prompt and effective treatment of symptomatic malaria,
anaemia and peripheral parasitaemia. It is also based on prevention of
malaria by chemoprophylaxis or intermittent treatment, regular screening and
personal protection to prevent vector contact e.g. use of Insecticide treated
bed nets (27).
World Health Organisation (WHO) recommends that for pregnant women in 
low transmission areas, an effective antimalaria drug should be provided on 
regular basis (28).
In highly endemic areas, WHO recommends intermittent treatment with an 
effective preferably one-dose of antimalarial drug should be available to 
women during the first and second trimester. Such intermittent treatment 
should be started from second trimester onwards and be given at intervals of 
not less than one-month (29).
The choice of drug for chemoprophylaxis or intermittent treatment in 
pregnancy should base on the drug efficacy, parasite resistance, drug cost, 
risk from malaria and adverse effects of prophylaxis (30).
Chloroquine (CQ) treatment was the chemoprophylaxis drug most widely 
used in Africa. As a consequence of this observation, Malawi, Kenya and
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Tanzania replaced CQ for malaria control in pregnancy with two treatment 
doses of SP in 1993, 1997 and 2001 respectively. The efficacy of CQ 
treatment declined rapidly during the 1980s (31).
The WHO advocates sulfadoxine-pyrimethamine (SP) for treatment in 
pregnancy of falciparum malaria resistant to CQ (32).
1.7 Questions to be addressed in this study:
The current practice of malaria control in some of African countries is using 
SP as the first-line antimalarial drug. These countries are Botswana, Kenya, 
Malawi, South Africa, Tanzania and Zambia. In these countries intermittent 
treatment during pregnancy is advocated. As more countries in malaria 
endemic areas consider changing their own antimalarial programmes from 
CQ to SP treatment during pregnancy, the evaluation of the effectiveness of 
this new SP intermittent treatment policy is essential for control malaria in 
pregnancy.
Studies have shown that SP intermittent treatment seems to be effective in 
preventing some of the consequences of malarial infection in pregnant women 
compared to CQ treatment (33). It has been agreed that SP treatment is useful 
for malarial infections with some chloroquine-resistance P. falciparum 
compared to chloroquine (34). However, it is not recommended to use SP 
before 16th week of pregnancy because of concerns on possible abnormalities 
in the fetus (35). One report reveals that the evidence of SP intermittent 
treatment on birth weight is weak (36). The side-effects of SP are rash, 
agranulocytosis, aplastic anaemia, thrombocytopenia, hypersensitivity,
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erythema, Steven Johnson’s syndrome, exfoliative dermatitis, glossitis, 
convulsions, headache, ataxia, hallucinations, tinnitus and hemolysis in G6PD 
deficiency (37). It has been reported from Mali that there is no significant 
difference in the rates of placental parasitaemia or low birth weight babies 
among women who received SP or CQ, in this area with chloroquine sensitive 
to P. falciparum malaria (38). Also, there are some indications that, 
chemoprophylaxis with chloroquine during pregnancy may have a protective 
effect, even in certain areas where chloquine-resistant P.falciparum is 
endemic (39). Therefore a meta-analysis has been undertaken on SP 
intermittent treatment studies in pregnancy so as to collate information on the 
benefit of this intervention on health outcomes. For this meta-analysis the 
following outcomes have chosen to evaluate the efficacy of SP intermittent 
treatment during pregnancy on;
(i) Severe anaemia in pregnant women.
(ii) Peripheral parasitaemia in pregnant women.
(iii) Placental parasitaemia in pregnant women.
(iv) Occurrence of low birth weight babies.
(v) Side effects in pregnant women.
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2.0 METHODS:
2.1 Search Strategy:
A computerized search of Medline, Cochrane Review, Pub Med and Google 
with the following key words; sulfadoxine-pyrimethamine, intermittent, 
pregnancy, Quasi-experimental studies and Randomised Control Trials 
retrieved the relevant articles. Published and unpublished relevant articles 
from January 1990 to December 2000 were used. Unpublished articles were 
used in order to avoid publication bias. The references of all identified relevant 
studies including reviews and meta-analyses were searched again in 
computer or hand searched in the Libraries for additional potential relevant 
publication. Also for the articles that were not found in full text respective 
authors were contacted.
2.2 Selection criteria:
Studies that were included in the systematic quantitative review met the 
following criteria;
• The comparison of treatment was SP/SP with CQ/CQ or placebo and 
not both (SP/CQ). The above comparison was selected because it is 
recommended schedule used in Tanzania, Malawi, Kenya and other 
countries.
• Strength of the effect between treatment and control group was tested.
• The study design was Randomised Control Trials and Quasi- 
experimental studies.
• Reports were in English only.
• Published and unpublished studies conducted from 1990 to 2000.
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2.3 Quality assessment:
A method for assessing the quality of a randomised control trial was used for 
all studies that were included in the study review (40).
All selected studies were assessed based on the following checklist;
• Was the allocation to the treatment groups really random?
• Was the treatment allocation concealed?
• Were the groups similar at baseline in terms of prognostics factors?
• Were the eligible criteria specified?
• Were outcome assessors blinded to the treatment allocation?
• Was the care provider blinded?
• Were the point estimates and measure of variability presented for the 
primary outcome measure?
• Data for at least one key outcome was analysed by “intention to treat”?
2.4 Data extraction:
For each of the study articles, three different reviewers one being a clinician 
extracted the following details.
• Study country
The name of country where the study was conducted was noted.
• Study date
The starting and finishing dates were jotted down.
• Study design
The study design was Randomised Control Trial or Quasi-experimental 
study.
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• Setting
The information on area where the study conducted was collected, 
based on malaria epidemiological and rural/urban areas.
• Sample size
The sample size of the study subjects was noted.
• Lost to follow-up
This is the number of study subjects who dropped out during the study.
• Participants
The women with their first or multiple pregnancy and gestation period 
were written down.
• Reported antimalarial regimens/ Intervention given
The intervention given during the study was noted; this was 
sulfadoxine-pyrimethamine, chloroquine or placebo depended on 
gestation at recruitment.
• Comparison regimens (Interested in the review)
The information collected here was only interested in this review; that 
is, the comparison of treatment was SP/SP (two-dose SP, with 
treatment doses -  1500 mg sulfadoxine and 75 mg pyrimethamine -  at 
enrolment and again early in the third trimester) and CQ/CQ (an initial 
treatment dose of CQ -  25 mg base/kg given as divided dose over a 
three-day period at enrolment followed by CQ -  300 mg base weekly 
until delivery) or placebo not both (SP/CQ). I selected these kinds of 
doses-interventions as recommended by WHO (29, 30, 32).
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• Outcome measures at delivery for comparison regimens.
The outcome measures to assess efficacy of sulfadoxine- 
pyrimethamine over chloroquine/placebo were recorded for 
comparison.
• Side effects
The adverse effects of sulfadoxine-pyrimethamine to pregnant women 
during the study were noted.
• Comments
Any significant information relevant to data extraction on individual 
study was noted down.
2.5 Data Analysis:
In order to avoid of the biased choice of published estimates, it was decided 
to calculate the actual estimates of risk ratios and protective efficacy with 95% 
confidence intervals using crude data as the authors presented them. Before 
calculating the protective efficacy, the Risk Ratio (RR) with 95% confidence 
intervals was determined to indicate comparison effect between women of 
those getting SP/SP and Chloroquine/Placebo in relation to failure and 
success in malaria prevention. Thereafter a calculation of the protective 
efficacy of double dose - sulphadoxine-pyrimethamine (SP/SP) compared with 
chloroquine/placebo at delivery was performed using the following formula; 
Protective efficacy = 100 x (1 -  Risk Ratio).
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The studies were considered in individual (without meta-analysis) and group 
(with meta-analysis) form for the calculation of risk ratios and protective 
efficacy with 95% confidence intervals.
The intercooled STATA 7.0 package was used to perform the estimates with 
graphical displays. The statistical significance was tested by the method of 
Mentel and Haenszel. This is a recommended method of summarizing results 
from several studies (41).
3.0 RESULTS:
3.1 Search outcomes:
The search of the computerised databases identified a total of 25 citations. 
After checking for doubles, and excluding studies clearly not related to the 
objective of our review, 13 papers and 1 abstract were considered in the 
selection procedure. Furthermore, looking on the inclusion criteria, 2 papers 
were finally included in the review. Efforts were made to secure full text of in 
study from Mali but in vain only abstract were obtained. Disagreements 
between the reviewers on individual items were identified and resolved during 
a consensus meeting. After 3 papers and1 abstract were properly reviewed 
and based on quality assessment only 2 papers were found to be proper for 
quantitative analysis, on the assumption that chloroquine and placebo has the 
same effect in an area where chloroqune-resistant P. falciparum is endemic. 
The rest citations were remained as relevant references.
The following flow diagram presents the number of abstracts and papers 
accepted and rejected by the three reviewers during the selection procedure.
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Figure 1: Flow diagram of papers accepted and rejected:
Therefore, based on checklist above, and summary of selected studies, the 
differences in study designs and settings across two selected studies can 
indicate that the results of some studies were more likely to be affected by 
bias than others. These studies were done in Kenya and Malawi. No study 
outside Africa was found that met inclusion criteria.
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The following table indicates a summary of quality assessment. 
Table 2 shows that study 1 was properly conducted as it fulfils all 
assessment criteria compared to study 2.
Table 2; Quality assessment of two trials included in a systematic review.
Assessment criteria Study
1
Study
2
Was the allocation to the 
treatment groups really random?
Yes No
Was the treatment allocation 
concealed?
Yes No
Were the groups similar at 
baseline in terms of prognostics 
factors?
Yes Yes
Were the eligible criteria 
specified?
Yes Yes
Were outcome assessors 
blinded to the treatment 
allocation?
Yes No
Was the care provider blinded? Yes No
Were the point estimates and 
measure of variability presented 
for the primary outcome 
measure?
Yes Yes
Data for at least one key 
outcome was analysed by 
“intention to treat”?
Yes No
Total Score 8/8 3/8
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3.2 Table of results for data analysis: 
(a) Presented without meta-analysis
Table 3: The outcome for peripheral parasitaemia in each trial;
Study SP group (n/N) Control group 
(n/N)
RR (95%CI) Protective 
efficacy in 
%(95%CI)
1 19/350 134/377 0.15 (0.10, 0.24) 85% (76%,90%)
2 2/71 12/38 0.09 (0.02, 0.38) 91 %(62%,98%)
Table 4: The outcome for placental parasitaemia in each trial;;
Study SP group (n/N) Control group 
(n/N)
RR (95%CI) Protective 
efficacy in 
%(95%CI)
1 16/205 29/196 0.53 (0.30, 0.94) 47%(6%,70%)
2 6/71 12/38 0.27 (0.11,0.66) 73%(34%,89%)
Table 5: The outcome for severe anaemia in eac l trial;
Study SP group (n/N) Control group 
(n/N)
RR (95%CI) Protective 
efficacy in 
%(95%CI)
1 50/350 88/378 0.61 (0.45, 0.84) 39%(16%,55%)
2 - - - -
Table 6: The outcome low birth weight in each trial;
Study SP group (n/N) Control group 
(n/N)
RR (95%CI) Protective 
efficacy in 
%(95%CI)
1 - - - -
2 12/71 10/38 0.64 (0.31, 1.35) 36%(-35%,69%)
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(b) Presented with meta-analysis.
According to the above results, it is only two parameters that can be 
statistically combined in meta-analysis on the peripheral and placental 
parasitaemia.
Table 7: The outcome for peripheral parasitaemia in two trials;
Study SP group 
(n/N)
Control group 
(n/N)
Weight
(%)
RR (95%CI) Protective efficacy in 
%(95%CI)
1 19/350 134/377 89.2 0.15(0.10, 0.24) 85% (76%-90%)
2 2/71 12/38 10.8 0.09 (0.02, 0.38) 91 %(62%-98%)
M-H pooled RR 0.14(0.09, 0.22) 86% (88%-91)
Test for heterogeneity chi-square = 0.48, df = 1, p = 0.487 
Test for overall effect of RR = 1: z = 8.67, p = 0.000
Figure 2: Relationship between peripheral parasitaemia and SP/SP use in 2 
published articles.
Study -
Risk ratio
(95% Cl) % Weight
Overall (95% Cl) o
0.15 (0.10,0.24) 
0.09 (0.02,0.38)
89.2
10.8
0.15 (0.09,0.23)
.021046 47.5144 
Risk ratio
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Table 8: The outcome for p acental parasitaemia in two trials
Study SP group 
(n/N)
Control group 
(n/N)
Weight
(%)
RR (95%CI) Protective efficacy in 
%(95%CI)
1 16/205 29/196 65.5 0.53 (0.30, 0.9) 47%(10%,70%)
2 6/71 12/38 34.5 0.27 (0.11, 0.66) 73%(34%,89%)
M-H pooled RR 0.44 (0.27, 0.71) 56% (29%,73%) 1
Test for heterogeneity chi-square = 1.56, df = 1, p = 0.212 
Test for overall effect of RR = 1: z = 3.37, p = 0.001
Figure 3: Relationship between placental parasitaemia and SP/SP use in 2 
published articles.
Study -
Risk ratio
(95% Cl) % Weight
1
2
0.53 (0.30,0.94) 65.5
0.27 (0.11,0.66) 34.5
Overall (95% Cl) 0.44 (0.27,0.71)
.109093 9.16648 
Risk ratio
The review found that two studies were homogeneous for combinability in 
clinically relevance based on test heterogeneity (table 7 and 8). This 
homogeneous facilitated sensible statistical meta-analysis to be done, since 
meta-analysis requires combination of at least two studies for producing 
overall estimate of the treatment effect (42).
The graphical display (Fig 2 and 3) has the vertical line drawn at relative ratio 
of one (unity) represents 'no effect’ and confidence interval overlapping this 
line represents the lack of a statistically significant effect. Therefore the both 
displays indicate the degree of decreasing peripheral and placental 
parasitaemia at significant levels since the overall confidence intervals do not 
overlapping lines, that is, statistically significant. Therefore, based on these
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studies, the efficacy of SP/SP against chloroquine on peripheral parasitaemia, 
placental parasitaemia, severe anaemia a LBW outcomes and whether 
intermittent SP/SP has adverse side effect or not was assessed.
4.0 DISCUSSION:
This quantitative systematic review evaluated the results of two papers on the 
efficacy of double dose sulfadoxine-pyrimethamine (SP/SP) treatment during 
pregnancy.
In combining data from two trials (study 1 and 2) gives the efficacy of 86% 
(95% Cl 78% to 91%) among the pregnant women got SP/SP during 
pregnancy against malaria peripheral infection with risk ratio (RR) of 0.14 
(95% Cl 0.09, 0.22), Table 7. This implies that SP/SP decreases the burden 
of peripheral parasitaemia compared to chloroquine/placebo, Fig 2. In 
supporting the outcome measure, it has been noted that SP/SP results in 
significantly reduced of peripheral malarial infection in primigravidae and 
multigravidae when compared to chloroquine (43).
Combining data from 2 studies resulted in a risk ratio of 0.44 for pregnant 
women who received SP/SP (95% Cl 0.27 to 0.71), which is equivalent to 
protective efficacy of 56% (95% Cl 29% to 73%) against malaria placental 
infection, Table 7. It means that SP/SP can reduce placental parasitaemia 
compared to chloroquine, Fig 3. In other words, SP/SP reduced the 
prevalence of placental parasitaemia at delivery by 56%. In addition to that it 
has been reported that SP/SP reduced placental infection among pregnant 
women compared to single dose of SP (44).
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Without meta-analysis, study 1 shows that the efficacy of SP/SP on severe 
anaemia which seemed to be less in comparison with peripheral and placental 
parasitaemia. Its protective efficacy was 39% with risk ratio of 0.61 (0.45,
0.84) as shown in table 5. It has been reported that two doses of SP might 
have little effect on severe anaemia at delivery (45). Not only malaria causes 
anaemia but also poor nutrition as causal factor for anaemia in pregnancy
(46) . This may be true since the study participants (from study 1 and study 2) 
came from rural settings where most inhabitants depend on subsistence 
farming. In order to reduce the risk of anaemia among pregnant mothers in 
rural setting, it is important to take care of provision of social services based 
on equity and poverty elevation programmes should implemented in such 
settings. For instance, poor infrastructures in rural areas like roads, this may 
limit equal distribution of insecticide treated nets for malaria prevention to be 
available in their areas, and therefore it would be useful to improve 
infrastructures in rural areas.
In considering study 2 alone, no protective efficacy was shown by SP/SP on 
LBW at delivery with comparison to chloroquine, its 95% Cl of risk ratio is 
across one, 0.64 (95% Cl 0.31, 1.35), as shown in table 6. The author 
suggested that extremely large sample sizes are required to detect 
statistically significant differences in LBW when controlling for the many 
causative factors for LBW. It should also be born in mind that the prevalence 
of LBW differs from country to country and is influenced by several factors
(47) . Other studies not included in the meta-analysis have shown that 2 doses 
of SP decreased LBW prevalence (44, 45, 48).
A few pregnant women reported adverse reactions of SP/SP (appendix 1 and 
2). It was stated that there was no evidence of a teratogenic or otherwise 
harmful effect of gestational exposure to SP (47). No pregnant mothers 
refused to take SP in both studies 1 and 2. This implies that there were not
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significant side effects that impeded pregnant women from using SP/SP 
treatment, and therefore this intervention can be recommended for wide scale 
use with a follow up of rare side effects.
The limitations of this meta-analysis fall into three categories, those 
attributable to the design of the reviewed studies, those attributable to the 
data available for analysis and those attributable to the combinability of 
parameters reported.
Only one study fulfilled the study design criteria set in the quality assessment, 
Table 1. Since the other study did not meet all the quality criteria, it was 
difficult to provide a reliable overall estimate for the efficacy of sulfadoxine - 
pyremethamine in pregnancy.
Given the inclusion criteria, the meta-analysis was limited in coverage with 
only two countries from Africa included. No suitable studies were found from 
outside Africa. This may limit the generalisability of the review results to 
malaria endemic areas in different settings.
Data for meta-analysis were combined on two parameters. These were 
peripheral and placental malaria infections. Data for severe anaemia and low 
birth weight outcome couldn’t be combined in more than one study. This could 
reduce lack of meta-analysis based evidence in these two parameters. In 
addition to that peripheral and placental parasitaemia are
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intermediate outcomes in pregnancy compared to severe anaemia and low 
birth weight outcome. As expected it was ease to demonstrate an impact of 
the SP intermittent therapy with intermediate outcomes (peripheral and 
placental parasitaemia) than definitive outcome (low birth weight).
The available evidence from this review was not consistent for the all 
outcomes. To establish the relative contribution of SP/SP treatment for all 
outcome measures in this review data from a CQ/CQ control was combined 
with placebo control and there was no indication in the revel of CQ resistance 
in the study areas hence the assumption of CQ/CQ = placebo may be wrong. 
Therefore, Randomised Control Trials should include comparison of the 
efficacy of CQ with SP as antimalarial treatment in preventing severe 
anaemia, LBW, peripheral and placental parasitaemia at once.
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5.0 Conclusion and recommendations:
Based on a meta-analysis of data from two prospective trials, it is concluded 
that double dose sulfadoxine-pyrimethamine (SP/SP) is potentially useful for 
pregnant women in areas where malaria is endemic 
More information is required regarding the efficacy and safety of intermittent 
treatment with SP/SP in different malaria endemic settings.
Therefore, further evidence about the efficacy of SP/SP is required.
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APPENDICES
Appendix 1: Study 1:
(Shulman et al CE. Intermittent sulfadoxine-pyremethamine to prevent severe anaemia 
secondary to malaria in pregnancy: a randomised placebo-controlled trial. The Lancet. 1999 
Vol 353)_____________________________________________________________________
Study country Kenya
Study date January, 1996 to April, 1997
Study design Randomised placebo-controlled trial
Setting Study took place in Kilifi, a mainly rural district on the 
coast of Kenya.
Sample size Randomised 1264 women.
Lost to follow-up 132 women.
Participants Women who were attending at Vipingo Health Centre. 
Women should be in their 1st pregnancy, between 16- 
and 30- weeks gestation.
The presence of peripheral parasitaemia was main 
determinant of severe anaemia.
Reported antimalarial 
regimens
SP/SP or placebo- depended on gestation at 
recruitment.
3 doses at 16 -19 weeks of gestation.
2 doses at 20 -  26 weeks of gestation.
1 dose at 27 -  30 weeks of gestation.
Comparison interventions 
(Interested in the review)
SP/SP or placebo;
2 doses at 20 -  26 weeks of gestation.
Outcome measures at 
delivery for comparison 
regimens.
Peripheral parasitaemia;
(Protective efficacy; 85% [76-90%] p< 0.0001)
Placebo group 35% (134/377) of women had infection. 
SP group 5% (19/350) of women had infection. 
Placental parasitaemia;
Placebo group 14.8% (29/196) of women had 
infection.
SP/SP group 7.8% (16/205) of women had infection. 
Severe anaemia;
(Protective efficacy; 39% [16-55%] p= 0.002)
Placebo group 23% (88/378) of women had severe 
anaemia.
SP group 14% (50/350) of women had severe 
anaemia.
Side effects of SP to 
women.
4 women in the SP group and 3 women in the placebo 
group were suspended because of suspected minor 
drug reaction.
Comments One and three doses of SP regimen were not 
interested in our review.
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Appendix 2: Study 2:
(Linda J. Shultz et al.The efficacy of antimalaria regimens containing sulfadoxine- 
pyrimethamine and/or chloroquine in preventing peripheral and placental plasmodium 
falciparum infection among women in Malawi. Am. J. Trop. Med. Hyg, 1994; 51,5: 515 - 522)
Study country Malawi
Study date 1st March to 20th October 1992
Study design Quasi-experimental study
Setting 70 villages with estimated total of population 60,000 in 
Mangochi districts in southern Malawi
Sample size Selected 357 women
Lost to follow-up 50 women.
Participants Women who were attending at antenatal clinics of two 
rural hospitals.
Women should be in their 1st or 2nd pregnancy, 
between 16- and 32- weeks gestation.
Reported antimalarial 
regimens
-CQ/CQ
-SP/CQ
-SP/SP
Comparison regimens 
(Interested in the review)
CQ/CQ -  an initial treatment dose of CQ at enrolment 
followed by CQ weekly until delivery.
SP/SP -  an initial treatment dose of SP with second 
dose at the beginning of the third trimester.
Outcome measures at 
delivery for comparison 
regimens.
Peripheral parasitaemia; (X2 -  test, p< 0.001)
CQ/CQ group 32% (12/38) of women had infection. 
SP/SP group 3%(2/71) of women had infection. 
Placental parasitaemia; (X2 -  test, p< 0.006)
CQ/CQ group 32% (12/38) of women had infection. 
SP/SP group 9% (6/71) of women had infection.
LBW outcome; (X2 -  test, p< 0.30)
CQ/CQ group 27% (10/38) of women had LBW 
babies.
SP/SP group 17% (12/71) of women had LBW babies.
Side effects of SP/SP to 
women.
Few women complain for side effects.
Comments The study included SP/CQ treatment regimen that 
was not interested in the review.
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